Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New immunosuppressive drugs: an update.

E Pohanka1

  • 1Department of Nephrology and Dialysis, Clinic of Internal Medicine III, University of Vienna, Medical School, Vienna, Austria. pohanka@nephro.imed3.akh-wien.ac.at

Current Opinion in Urology
|February 27, 2001
PubMed
Summary

New immunosuppressive drugs offer personalized treatment options. This review details current and novel agents, aiding clinicians in selecting optimal immunosuppression strategies for patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dialysis in diabetic patients: hemodialysis and peritoneal dialysis. Pros and cons.

Minerva urologica e nefrologica = The Italian journal of urology and nephrology·2012
Same author

Geographical prevalence, risk factors and impact of hepatitis B and C after renal transplantation.

Clinical nephrology·2009
Same author

Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2008
Same author

Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy.

Transplantation proceedings·2007
Same author

Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2007
Same author

Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic).

Clinical nephrology·2006

Area of Science:

  • Immunopharmacology
  • Drug Development

Background:

  • The last few decades have seen a significant increase in available immunosuppressive drugs.
  • Understanding of drug mechanisms and side effects has evolved, leading to improved therapies.

Purpose of the Study:

  • To provide an updated review of key immunosuppressive agents.
  • To survey novel immunosuppressive drugs with future therapeutic potential.

Main Methods:

  • Literature review of established and emerging immunosuppressive drugs.
  • Analysis of drug classes including calcineurin inhibitors, mTOR inhibitors, gene expression regulators, and purine/pyrimidine synthesis inhibitors.

Main Results:

  • Established immunosuppressants' efficacy and mechanisms are better understood.

Related Experiment Videos

  • Newer agents offer synergistic effects or reduced adverse events.
  • A wide array of immunosuppressive options now exists for tailored patient care.

    • Conclusions:

    • Comprehensive knowledge of immunosuppressive drugs is crucial for optimal patient management.
    • The review highlights current important agents and future novel therapies.